Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1<sup>st</sup> line therapy for adult patients with diffuse large B-cell lymphoma
Aim. To assess the pharmacoeconomic feasibility of using polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in 1st line therapy of adult patients with diffuse large B-cell lymphoma in the Russian healthcare system, taking into account the curren...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-03-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/801 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|